Literature DB >> 20953653

Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008.

S Hawser1, D Hoban, S Bouchillon, R Badal, Y Carmeli, P Hawkey.   

Abstract

As part of the worldwide Study for Monitoring Antimicrobial Resistance Trends (SMART), a total of 3,030 clinical isolates of gram-negative bacilli from intra-abdominal infections were collected from 43 hospital centres from 13 European countries during 2008. Of 51 species, the most commonly isolated species were Escherichia coli (49.3%), followed by Klebsiella pneumoniae (10.5%) and Pseudomonas aeruginosa (8.6%). Respectively, 17.9%, 11.6%, 5.5% and 4.5% of K. pneumoniae, E. coli, Proteus mirabilis and K. oxytoca were extended-spectrum beta-lactamase (ESBL)-positive. All isolates were tested using a panel of 12 antimicrobial agents, and susceptibilities were determined using European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. The most active agents against the study isolates (including those producing ESBLs) were amikacin, ertapenem and imipenem. Overall, with the exception of the carbapenems, most agents exhibited dramatically reduced susceptibilities against ESBL-positive and multi-drug-resistant isolates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20953653     DOI: 10.1007/s10096-010-1066-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Increasing multidrug resistance and limited treatment options: situation and initiatives in Europe.

Authors:  K G Kristinsson; D L Monnet
Journal:  Euro Surveill       Date:  2008-11-20

2.  EUCAST technical note on Amphotericin B.

Authors:  C Lass-Flörl; M C Arendrup; J-L Rodriguez-Tudela; M Cuenca-Estrella; P Donnelly; W Hope
Journal:  Clin Microbiol Infect       Date:  2011-10-19       Impact factor: 8.067

3.  High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.

Authors:  Shiri Navon-Venezia; Azita Leavitt; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-03-12       Impact factor: 5.790

4.  Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.

Authors:  S Nijssen; A Florijn; M J M Bonten; F J Schmitz; J Verhoef; A C Fluit
Journal:  Int J Antimicrob Agents       Date:  2004-12       Impact factor: 5.283

5.  Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain.

Authors:  Tânia Curiao; María Isabel Morosini; Patricia Ruiz-Garbajosa; Ana Robustillo; Fernando Baquero; Teresa M Coque; Rafael Cantón
Journal:  J Antimicrob Chemother       Date:  2010-05-30       Impact factor: 5.790

6.  In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Authors:  Grant V Bochicchio; Fernando Baquero; Po-Ren Hsueh; David L Paterson; Flávia Rossi; Theresa A Snyder; Kathleen McCarroll; Vilas Satishchandran; Mark J Dinubile; Joseph W Chow
Journal:  Surg Infect (Larchmt)       Date:  2006-12       Impact factor: 2.150

7.  Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.

Authors:  Ralf Rene Reinert; Donald E Low; Flávia Rossi; Xiaojiang Zhang; Chand Wattal; Michael J Dowzicky
Journal:  J Antimicrob Chemother       Date:  2007-09-13       Impact factor: 5.790

8.  Outbreak caused by a multidrug-resistant Klebsiella pneumoniae clone carrying blaVIM-12 in a university hospital.

Authors:  Despina Tokatlidou; Maria Tsivitanidou; Spyros Pournaras; Alexandros Ikonomidis; Athanassios Tsakris; Danae Sofianou
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

9.  Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece.

Authors:  Spyros Pournaras; Efthimia Protonotariou; Evangelia Voulgari; Ioulia Kristo; Evangelia Dimitroulia; Danai Vitti; Maria Tsalidou; Antonios N Maniatis; Athanassios Tsakris; Danai Sofianou
Journal:  J Antimicrob Chemother       Date:  2009-06-13       Impact factor: 5.790

10.  Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient.

Authors:  Moran G Goren; Yehuda Carmeli; Mitchell J Schwaber; Inna Chmelnitsky; Vered Schechner; Shiri Navon-Venezia
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

View more
  5 in total

1.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Densities and antimicrobial resistance of Escherichia coli isolated from marine waters and beach sands.

Authors:  Vanessa da Costa Andrade; Bruna Del Busso Zampieri; Eliete Rodrigues Ballesteros; Aline Bartelochi Pinto; Ana Julia Fernandes Cardoso de Oliveira
Journal:  Environ Monit Assess       Date:  2015-05-12       Impact factor: 2.513

3.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Belén Gutiérrez-Gutiérrez; Salvador Pérez-Galera; Elena Salamanca; Marina de Cueto; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina; Alicia Hernández; Mario Venditti; Nuria Prim; Julia Origüen; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J Schwaber; Joaquín Bermejo; Warren Lowman; Po-Ren Hsueh; Marta Mora-Rillo; Clara Natera; Maria Souli; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

4.  Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

Authors:  Joseph Solomkin; Ellie Hershberger; Benjamin Miller; Myra Popejoy; Ian Friedland; Judith Steenbergen; Minjung Yoon; Sylva Collins; Guojun Yuan; Philip S Barie; Christian Eckmann
Journal:  Clin Infect Dis       Date:  2015-02-10       Impact factor: 9.079

5.  Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infections in Taiwan.

Authors:  Cheng-Yen Kao; Shu-Sheng Chen; Kuei-Hsiang Hung; Hsiu-Mei Wu; Po-Ren Hsueh; Jing-Jou Yan; Jiunn-Jong Wu
Journal:  BMC Microbiol       Date:  2016-06-13       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.